Yefu Wang

Prof. Dr. Yefu Wang

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2022 in Molecules
Verified
Journal Article
Open access
PDF file
YAYang Ai
Yang Ai
SLSang Luo
Sang Luo
BWBen Wang
Ben Wang
SXShuai Xiao
Shuai Xiao
YWYefu Wang
Yefu Wang
TDO2 is a key enzyme in the kynurenine metabolic pathway, which is the most important pathway of tryptophan metabolism. It has been shown that miRNAs are involved in cell metastasis through interaction with target mRNAs. In this study, we found 645 miRNAs that could be immunoprecipitated with TDO2 through the RNA-immunoprecipitation experiment. miR-126-5p was selected as the research target, which was also confirmed by dual-luciferase reporter assay. Through qRT-PCR analysis, it was verified that the overexpression of miR-126-5p promoted the expression of TDO2, PI3K/AKT and WNT1. Meanwhile, it was verified that overexpression of miR-126-5p can promote intracellular tryptophan metabolism by HPLC. We also verified the effects of miR-126-5p on cell proliferation, migration, and invasion by cck-8, cell colony formation and trans-well assay in both HCCLM3 cells and HepG2 cells. In vivo experiments were also conducted to verify that miR-126-5p promoted tumor formation and growth via immunohistochemical detection of cell infiltration and proliferation to generate markers Ki-67, BAX, and VEGF. In conclusion, our results suggest that miR-126-5p is a biomarker and a potential new treatment target in the progression of HCC via promoting the expression of TDO2.

1 March 2017 in Process Biochemistry
Verified
Journal Article
Closed access
KZKangping Zhou
Kangping Zhou
YDYanshan Dong
Yanshan Dong
HZHao Zheng
Hao Zheng
BCBin Chen
Bin Chen
RMRuifeng Mao
Ruifeng Mao
YWYefu Wang
Yefu Wang

Verified
Journal Article
Open access
PDF file
YAYang Ai
Yang Ai
BWBen Wang
Ben Wang
SXShuai Xiao
Shuai Xiao
SLSang Luo
Sang Luo
YWYefu Wang
Yefu Wang
Tryptophan metabolism plays a role in the occurrence and development of hepatocellular carcinoma cells. By degrading certain amino acids, tumor growth can be limited while maintaining the body’s normal nutritional requirements. Tryptophan side-chain oxidase (TSO) enzyme can degrade tryptophan, and its inhibitory effect on hepatocellular carcinoma cells is worthy of further study. To investigate the degradation effect on tryptophan, TSO was isolated and purified from qq Pseudomonas. The reaction products were identified with high performance liquid chromatography (HPLC) and high-performance liquid chromatography tandem mass spectrometry (HPLC-MS). De novo sequencing provided the complete amino acid sequence of TSO. The results of CCK-8, colony formation, transwell, and qPCR confirmed that TSO had inhibitory effects on the proliferation and migration of HCCLM3 (human hepatocarcinoma cell line) and HepG2 cells. The results of flow cytometry confirmed its apoptotic activity. In animal experiments, we found that the tumor-suppressive effect was better in the oncotherapy group than the intraperitoneal injection group. The results of immunohistochemistry also suggested that TSO could inhibit proliferation and promote apoptosis. In conclusion, a specific enzyme that can degrade tryptophan and inhibit the growth of hepatoma cells was authenticated, and its basic information was obtained by extraction/purification and amino acid sequencing.

1 July 2021 in Annals of Translational Medicine
Verified
Journal Article
Open access
PDF file
SLSang Luo
Sang Luo
YAYang Ai
Yang Ai
SXShuai Xiao
Shuai Xiao
BWBen Wang
Ben Wang
YWYefu Wang
Yefu Wang
Background: Because the liver is central to the physiology of the body, primary hepatocytes are widely used in liver pathology and physiological research, such as liver drug screening, bioartificial liver support system, and cell therapy for liver diseases. However, the source of primary hepatocytes is limited. We describe a novel non-transgenic protocol that facilitates the rapid generation of hepatocyte-like cells from human umbilical cord-derived mesenchymal stem cells (hUC-MSCs), providing a new source of functional hepatocytes. Methods: In this study, we used hUC-MSCs and human induced pluripotent cells (iPSCs) derived mesenchymal stem cells (iMSCs) to investigate the new induction strategy. Passage 3 MSCs were induced into hepatocyte-like cells using small-molecule compounds combined with cell factors in vitro. Functional hit 1 (FH1), a promising small molecule compound was achieved to replace HGF in the hepatocyte maturation stage to induce the hepatocyte-like cells differentiation. Results: We rapidly induced hUC-MSCs and human iMSCs into hepatocyte-like cells within 10 days in vitro, and the cells were morphologically similarly to both hepatocytes derived from the hepatocyte growth factor (HGF)-based method and the primary hepatocytes. They expressed mature hepatocyte special genes and achieved functions such as glycogen storage, albumin expression, urea secretion, cytochrome P450 activity, Low-density lipoprotein (LDL) uptake, and indocyanine green (ICG) uptake. Conclusions: We successfully established a small-molecule protocol without using HGF to differentiate MSCs into hepatocyte-like cells, which provides a rapid and cost-effective platform for in vitro studies of liver disease.

1 January 2022 in Journal of Functional Foods
Verified
Journal Article
Open access
Yiping TangYiping Tang
Yiping Tang
YYYuanyuan Yang
Yuanyuan Yang
XLXuan Lu
Xuan Lu
QLQiuchen Liu
Qiuchen Liu
QLQiaohong Li
Qiaohong Li
YWYefu Wang
Yefu Wang

1 June 2010
Verified
Conference Paper
Closed access
YWYefu Wang
Yefu Wang
RDRobert Deaver
Robert Deaver
XWXiaorui Wang
Xiaorui Wang
Many power management strategies have been proposed for enterprise servers based on dynamic voltage and frequency scaling (DVFS), but those solutions cannot further reduce the energy consumption of a server when the server processor is already at the lowest DVFS level and the server utilization is still low (e.g., 5% or lower). To achieve improved energy efficiency, request batching can be conducted to group received requests into batches and put the processor into sleep between the batches. However, it is challenging to perform request batching on a virtualized server because different virtual machines on the same server may have different workload intensities. Hence, putting the shared processor into sleep may severely impact the performance of all the virtual machines. This paper proposes Virtual Batching, a novel request batching solution for virtualized servers with primarily light workloads. Our solution dynamically allocates CPU resources such that all the virtual machines can have approximately the same performance level relative to their allowed peak values. Based on this uniform level, our solution determines the time length for periodically batching incoming requests and putting the processor into sleep. When the workload intensity changes from light to moderate, request batching is automatically switched to DVFS to increase processor frequency for performance guarantees. Empirical results based on a hardware testbed and real trace files show that Virtual Batching can achieve the desired performance with more energy conservation than several well-designed baselines, e.g., 63% more, on average, than a solution based on DVFS only.